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Purpose: The prevalence of metabolic syndrome (MetS) generally varies depend-
ing on its diagnostic definition, and many different definitions inevitably lead to 
substantial confusion and lack of comparability between studies. Despite extensive 
research, there is still no gold standard for the definition of MetS, which continues 
to be a matter of debate. In this study, we investigate whether and to what extent 
its individual components are related to the risk of cardiovascular disease (CVD) 
in Korean population. Materials and Methods: We used data from the 2005 Ko-
rea National Health and Nutrition Examination Survey, which is a nationally rep-
resentative survey of the noninstitutionalized civilian population. The study sam-
ple consisted of 1,406 Korean adults (587 men, 819 women) who were diagnosed 
with MetS based on the revised National Cholesterol Education Program (NCEP) 
criteria. Central obesity is defined as a waist circumference cutoff point reported in 
Asia-Pacific criteria for obesity based on waist circumference by the World Health 
Organization. CVD was defined as presence of stroke, myocardial infarction, or 
angina pectoris on a medical history questionnaire. Results: The CVD prevalence 
among the subjects was 6.8% for men and 8.6% for women. Besides age, the com-
ponents of MetS showing a significant difference in the number of CVD events 
were high fasting glucose (FG) in men and high blood pressure (BP) and high FG 
in women. After adjusting for gender and age, high FG was shown to yield a sig-
nificant difference (odds ratio: unadjusted 2.08, adjusted 1.81), alone among all 
MetS components. However, after adjusting for only age, no significant difference 
was found. Conclusion: Fasting glucose level is the highest predicting factor for 
CVD in Korean patients with MetS based on the revised NECP definition.
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INTRODUCTION
Metabolic syndrome (MetS) is characteristically defined as a clustering condition CV Predictability of Each Component in MetS
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by lower cutoff points for specific metabolic components or 
different criteria applied based on ethnicity, more critical is-
sues, such as designating which components are essential, 
have led to large differences in prevalence.9,10 So far, the 
majority of research into diagnostic criteria for MetS has 
been done in studies that support specific criteria by com-
paring the prevalence11 or prospective incidence12,13 of CVD 
in people who satisfy each criterion. Rarely have there been 
studies that investigate the relationship between each com-
ponent and the prevalence of CVD,14,15 and all previous 
studies have examined only the general population. In addi-
tion to metabolic components, however, there are many 
other factors that increase the risk of CVD. Thus, in order 
to compare the predictability of metabolic components for 
CVD, it would be more appropriate to study patients who 
have been diagnosed with MetS. 
The purpose of the study was to investigate the relation-
ship between the prevalence of CVD and each metabolic 
component using nationwide data for Koreans who were 
diagnosed with MetS according to the NCEP guidelines, in 
which specific factors were not weighted.
MATERIALS AND METHODS
Study population and data collection
This study was based on data obtained from the Third Ko-
rean National Health and Nutrition Examination Survey 
(KNHANES) of noninstitutionalized Korean civilians, which 
of cardiovascular risk factors including hyperglycemia, 
dyslipidemia, hypertension, and central obesity.1 It can not 
only progress to overt diabetes2-4 but also has close relation-
ship with development and prognosis of cardiovascular dis-
ease (CVD).5 Although there have been questions as to 
whether MetS predicts CVD beyond its individual compo-
nents,6 it is still meaningful to look into its diagnosis, man-
agement, and prevention in medicine or public health. 
Despite the fact that the pathophysiology of MetS is yet 
not clearly known, it has been suggested that an increasing-
ly sedentary life style and western dietary habits play a role 
in developing obesity and dysfunctional energy storage, 
which can mediate insulin resistance as well as the interac-
tion of genetic factors, thereby contributing to recent trends.7 
With the rising obese population and worldwide life expec-
tancy, the frequency of development of MetS does not 
seem to diminish for the foreseeable future.8
The conception of MetS has evolved since it was first de-
fined by Reaven in 1988 to improve the understanding of 
links between insulin resistance and vascular disease. Sev-
eral definitions have been introduced including the World 
Health Organization criteria, which emphasizes hypergly-
cemia and insulin resistance; the National Cholesterol Edu-
cation Program (NCEP) guideline, which deems all meta-
bolic components as equally important; and the International 
Diabetes Federation (IDF) definition, which regards central 
obesity as a necessary factor (Table 1). These diverse defini-
tions have led to substantial confusion and to an inability to 
compare study results. Although confusion might be caused 
Table 1. Metabolic Syndrome Definitions from WHO, NCEP, and IDF
WHO (1999) NCEP (2001) IDF (2005)
Required Insulin resistance*
WC† ≥ 94 cm in men or 
≥ 80 cm in women
No. of abnormalities ≥ 2 of: ≥ 3 of: ≥ 2 of:
Obesity
WHR > 0.9 in men or > 0.85 in 
women; BMI ≥ 30 kg/m
2
WC ≥ 102 cm in men or  
≥ 88 cm in women
Triglycerides ≥ 150 mg/dL  ≥ 150 mg/dL ≥ 150 mg/dL
HDL cholesterol
< 40 mg/dL in men or 
< 50 mg/dL in women
< 40 mg/dL in men or 
< 50 mg/dL in women
< 40 mg/dL in men or 
< 50 mg/dL in women
Hypertension ≥ 140/90 mmHg ≥ 130/85 mmHg ≥ 130/85 mmHg
Glucose ≥ 110 mg/dL‡ ≥ 100 mg/dL
Microalbuminuria
Albumin/creatinine ratio > 30 mg/g; 
Albumin excretion rate > 20 mcg/min
WHO, World Health Organization; NCEP, National Cholesterol Education Program; IDF, international diabetes federation, WC, waist 
circumference; WHR, waist to hip ratio; BMI, body mass index; HDL, high density lipoprotein.
*Insulin resistance in top 25%; glucose ≥ 110 mg/dL; 2-hour glucose ≥ 140 mg/dL.
†Waist circumference for Europids (someone of European Extraction, even if living elsewhere). 
‡The American Diabetes Association recently suggested lowering this threshold to 100.In-Cheol Hwang, et al.
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cording to the presence of CVD were done by χ2 test, and 
odds ratios (OR) were calculated using multiple logistic re-
gression analysis to evaluate the predictability of each meta-
bolic component. All data are summarized as mean ± stan-
dard deviation or number (%). 
RESULTS
There were 1,406 subjects (587 males and 819 females) di-
agnosed with MetS according to the revised NCEP defini-
tion out of a total of 5,030 (2,076 males and 2,954 females). 
The mean age of those diagnosed was 51.8 ± 13.2 for men 
(28.3%) and 58.1 ± 13.2 years for women (27.7%). Infor-
mation regarding various metabolic risk factors is shown in 
Table 2. CVD events occurred in 6.9% of men and 8.6% of 
women. Among these events, stroke occurred with the high-
est frequency for both men and women. 
Table 3 shows differences in the percentage of CVD 
events based on each metabolic risk factor. The CVD group 
was significantly older than the non-CVD group in both 
men and women. In addition, there was a significant differ-
ence in high fasting glucose (FG) in men and high blood 
pressure (BP) and high FG in women. The percentage of 
current smokers or who had high triglyceride was higher in 
the non-CVD group; however, this was statistically insig-
nificant. This is not irrelevant, considering standards of Ko-
rean health insurance coverage for lipid-lowering drugs and 
reverse causality due to cross sectional design.
Logistic regression analysis of CVD events for each 
component of MetS prior to correction showed that high 
BP and high FG were statistically significant (OR: high BP 
2.16, high FG 2.08). After adjustment for age and gender, 
only high FG showed significance (OR 1.81)(Fig. 1). Gen-
der differences, presented in Table 4, show that prior to ad-
justment, fasting glucose in men (OR 2.67, 95% CI 1.24-
5.75) and high BP (OR 2.09, 95% CI 1.10-3.96) and high FG 
(OR 1.84, 95% CI 1.10-3.10) in women were significant. 
However, after being adjusted, no significant difference 
was found in either men or women.
c a DISCUSSION
We analyzed the relationship between the prevalence of 
CVD and each metabolic component in a target population, 
which was not representative of the general population, but 
was conducted by the Korean Ministry of Health and Wel-
fare in 2005. Detailed descriptions of the survey method 
have been provided elsewhere.16 Briefly, this survey was a 
nationwide representative study that used a stratified, multi-
stage probability sampling design for the selection of house-
hold units. This survey was composed of four parts: health 
interview, health behavior, health examination, and nutri-
tion. The surveys were performed during face-to-face inter-
views with the family members of randomly selected house-
holds. We performed a cross-sectional analysis of the data 
from the subjects who completed the health interview and 
health behavior survey. We excluded individuals with in-
complete data for the standardized physical examination, 
laboratory tests, and anthropometric measures. This result-
ed in a final analytical sample of 1,406 subjects (587 men, 
819 women) with MetS among the 5,030 participants aged 
19 years or older. The presence of CVD was defined as a 
physician’s diagnosis of any of the following on the Health 
Interview Survey: stroke, myocardial infarction, and angina. 
Smokers were defined as those who were currently smoking 
at the time of the survey, regardless of the number of ciga-
rettes smoked. Participants who exercised twice a week, re-
gardless of type or length of the exercise, were considered to 
partake in exercise.
Definition of the MetS
We used the revised NCEP criteria,17 which were proposed 
by the National Heart, Lung, and Blood Institute/American 
Heart Association, and require at least three of the following 
components: 1) abdominal obesity (waist circumference ≥ 
90 cm for Asian men or ≥ 80 cm for Asian women),18 2) tri-
glycerides ≥ 150 mg/dL or receiving drug treatment, 3) 
high density lipoprotein (HDL) cholesterol < 40 mg/dL for 
men or < 50 mg/dL for women or receiving drug treatment, 
4) systolic/diastolic blood pressure ≥ 130/85 mmHg or re-
ceiving drug treatment and 5) fasting plasma glucose ≥ 100 
mg/dL or receiving drug treatment. The revised NCEP crite-
ria had recommended a lower waist circumference cutoff for 
Asian-Americans because Asians are predisposed to insulin 
resistance, MetS, and type 2 diabetes at lower waist circum-
ferences than Caucasians. 
Statistical analysis
Statistical analysis was performed using STATA SE 9 (STA-
TA Corporation, Texas, USA) and p values of < 0.05 were 
considered to be statistically significant. Comparisons of 
the number of patients with each metabolic risk factor ac-CV Predictability of Each Component in MetS
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5.19, and after adjustment it was 2.50 (not shown in table).
In the present study, we found that the only significant 
factor relevant to CVD prevalence was high FG. Anderson, 
et al.14 showed that high FG (OR = 1.23, 95% CI 1.06-1.43) 
and Low HDL (OR = 1.57, 95% CI 1.31-1.89) were signifi-
cantly different among the individual MetS factors at risk 
for coronary artery disease after adjusting for age. Howev-
er, secondary analysis for the risk of death or myocardial 
infarction showed that only high FG was significant (ad-
justed hazard ratio 1.46, 95% CI 1.17-1.82). Sixty-five per-
cent of subjects had undergone coronary angiography at the 
start of the study because they were at high risk for coro-
was made up of patients who had been diagnosed with 
MetS using the revised NCEP criteria. The purpose of se-
lecting these subjects would be first to clarify the differenc-
es for each factor associated with MetS; and second, to 
minimize the influence of risk factors other than metabolic 
components that may increase the risk of CVD. In this study, 
when additional analysis was performed on the general 
population of 5,030 subjects, we found that the factors 
showing significant differences between the groups with 
and without CVD numbered three for the men (excluding 
lipid abnormalities) and five for women. Before adjusting 
for age and smoking, the OR of women with high BP was 
Table 2. General Characteristics of Study Subjects* by Gender 
Men  Women 
Number 587 819
Age, yrs   51.8 ± 13.2 58.1 ± 13.2
Current smoker, n (%) 248 (42.3) 51 (6.2)
Exerciser†, n (%) 266 (45.3) 313 (38.2)
Total cholesterol, mg/dL 189.6 ± 34.1 197.0 ± 36.5
LDL cholesterol, mg/dL 113.5 ± 31.7 123.8 ± 33.1
HDL cholesterol, mg/dL 37.3 ± 7.2 41.0 ± 7.7
Fasting glucose, mg/dL 107.6 ± 28.9 104.6 ± 27.3
Systolic blood pressure, mmHg 130.9 ± 15.8 130.6 ± 19.1
Diastolic blood pressure, mmHg 86.1 ± 9.9   81.0 ± 10.1
Triglycerides, mg/dL 194.5 ± 73.9 161.3 ± 69.8
Waist circumference, cm 91.3 ± 6.8 86.9 ± 7.5
CVD events‡, n (%) 40 (6.8) 70 (8.6)
Stroke 23 (3.9) 36 (4.4)
MI   8 (1.4) 10 (1.2)
Angina 11 (1.9) 29 (3.5)
LDL, low density lipoprotein; HDL, high density lipoprotein; CVD, cardiovascular disease; MI, myocardial infarction.
*All subjects were diagnosed with metabolic syndrome by National Cholesterol Education Program criteria.
†Subjects who exercise more than twice a week.
‡Diagnosed by physician as any of the followings: stroke, MI, or angina.
Table 3. Comparison of Frequency of Metabolic Risk Factors According to the Presence of Cardiovascular 
Disease
Men Women
No CVD CVD p value* No CVD CVD p value*
Number 547 40 749 70
Age, mean (SD) 51.15 (13.2) 60.60 (9.49) < 0.001 57.40 (13.29) 65.26 (9.65) < 0.001
Current smoker, n (%) 237 (43.33) 11 (27.50) 0.050 44 (5.87)  7 (10.00) 0.172
Exercise, n (%) 243 (44.42) 23 (57.50) 0.109 284 (37.92) 29 (41.43) 0.563
Abdominal obesity, n (%) 346 (63.25) 26 (65.00) 0.825 658 (87.85) 61 (87.14) 0.863
Triglycerides, n (%) 417 (76.23) 25 (62.50) 0.052 414 (55.27) 36 (51.43) 0.536
Low-HDL cholesterol, n (%) 415 (75.87) 32 (80.00) 0.554 690 (92.12) 65 (92.86) 0.827
Blood pressure, n (%) 432 (78.98) 36 (90.00) 0.094 523 (69.83) 57 (81.43) 0.041
Fasting blood glucose, n (%) 305 (55.16) 30 (75.00) 0.018 356 (47.53) 42 (60.00) 0.046
HDL, high density lipoprotein; CVD, cardiovascular disease.
*Independent two sample t-test or χ2 test were used.In-Cheol Hwang, et al.
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obesity in recent publications of the pathological mecha-
nisms of MetS.19 However, recent studies are somewhat 
skeptical of considering central obesity as a necessary com-
ponent,20,21 and we found no difference in central obesity 
between individuals with and without CVD, in both men 
and women. The second major controversy is that there are 
many other factors that have a great impact on risk for 
CVD besides the five metabolic components of the criteria, 
including age.22,23 These components should also be consid-
ered in the diagnosis of MetS. In our study, the prevalence 
of CVD increased 1.76 times for men and 1.66 times for 
women with every 10 year increase in age, and this result 
nary artery disease. More than 70% were found to have ste-
nosis. Although this cannot be directly compared with our 
study, the results also show that high FG had a strong corre-
lation with prevalence of CVD, similar to previous reports.
There is still some major controversy regarding the diag-
nostic criteria for MetS. One of these is regarding which 
criterion is the most appropriate. So far, various diagnostic 
criteria for MetS have been published based on the require-
ments of specific components. The IDF presented new di-
agnostic criteria that considers racial differences and also 
considers central obesity as a necessary component based 
on its strong correlation with insulin resistance and central 
Table 4. Predictability of Each Metabolic Component for Cardiovascular Disease by Logistic Regression Anal-
ysis According to Gender
Men (n = 587) Women (n = 819)
Crude OR 
(95% CI)
p value
Age-adjusted* 
OR (95% CI)
p value
Crude OR 
(95% CI)
p value
Age-adjusted* 
OR (95% CI)
p value
Abdominal 
  obesity
1.13 
(0.55 - 2.29)
0.740
1.15 
(0.56 - 2.39)
0.702
1.17 
(0.55 - 2.50)
0.676
1.18 
(0.55 - 2.57)
0.668
Triglycerides
0.70 
(0.34 - 1.42)
0.322
0.86 
(0.41 - 1.80)
0.692
1.05 
(0.63 - 1.73)
0.863
1.08 
(0.64 - 1.80)
0.781
Low-HDL 
  cholesterol
1.91 
(0.83 - 4.40)
0.129
1.95 
(0.84 - 4.57)
0.122
1.49 
(0.57 - 3.93)
0.417
1.46 
(0.55 - 3.90)
0.446
Blood pressure
2.53 
(0.86 - 7.45)
0.092
2.05 
(0.68 - 6.19)
0.201
2.09 
(1.10 - 3.96)
0.024
1.38 
(0.71 - 2.69)
0.340
Fasting blood 
  glucose
2.67 
(1.24 - 5.75)
0.012
2.08 
(0.95 - 4.59)
0.067
1.84 
(1.10 - 3.10)
0.021
1.69 
(0.99 - 2.86)
0.051
OR, odds ratio; CI, confidence interval; HDL, high density lipoprotein.
*Age was stratified into intervals of 10 years.
Fig. 1. Odds ratio of each metabolic component for occurrence of cardiovascular events in all subjects. WC, waist circumference; TG, tri-
glycerides; HDL, high density lipoprotein; BP, blood pressure; FG, fasting glucose.
High WC
High TG
Low HDL
High BP
High FG
Crude
Adjusted
Crude
Adjusted
Crude
Adjusted
Crude
Adjusted
Crude
Adjusted
0.5 0.6 0.7 0.8 0.9 1.0
Odds ratio
1.5 2.0 2.5 3.0 3.5 4.0
1.26
1.19
0.88
0.99
1.81
1.79
2.16
1.55
2.08
1.81CV Predictability of Each Component in MetS
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CVD events in patients with MetS was considerably di-
verse, and high FG had the highest of all of them. In pa-
tients with MetS diagnosed according to the revised NCEP 
criteria, aggressive management should be undertaken to 
reduce all standard risk factors, but particular and increased 
attention should be paid to preventing and treating diabetes. 
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